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Magnesium has been implicated in regulating blood pressure and vascular endothelial cell 
function, but its role in the pathophysiology of intracranial aneurysm is not known. Here we 
performed a Mendelian randomization analysis to investigate the association between serum 
magnesium concentration and risk of intracranial aneurysm.  
Methods 
Five single-nucleotide polymorphisms strongly associated with serum magnesium 
concentrations in a genome-wide association study in 23 829 individuals of European 
ancestry were used as genetic instruments. Genetic association estimates for intracranial 
aneurysm were obtained from a genome-wide association study in 79 429 individuals (7495 
cases and 71 934 controls). The inverse-variance weighted method was used in the primary 
analyses to obtain the causal estimates. 
Results 
Higher genetically predicted serum magnesium concentrations were associated with lower 
risk of intracranial aneurysm. The odds ratios per 0.1 mmol/L increment in genetically 
predicted serum magnesium concentrations were 0.66 (95% confidence interval: 0.49-0.91) 
for intracranial aneurysm (unruptured and ruptured combined), 0.57 (95% confidence 
interval: 0.30-1.06) for unruptured intracranial aneurysm, and 0.67 (95% confidence interval: 
0.48-0.92) for aneurysmal subarachnoid hemorrhage.  
Conclusion 
This study provides evidence to support that increased serum magnesium concentrations 
reduce the risk of intracranial aneurysm and associated hemorrhage. 
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Intracranial aneurysm rupture and resultant subarachnoid hemorrhage is associated with a 
high rate of morbidity and mortality.1, 2 Serum magnesium concentrations have been 
implicated in regulating blood pressure and function of the vascular endothelium.3-5 
However, whether increased serum magnesium concentrations affect the risk of intracranial 
aneurysm and related subarachnoid hemorrhage is not known.  
To investigate this, we leveraged randomly allocated genetic variants related to serum 
magnesium concentrations as instrumental variables in a two-sample Mendelian 
randomization (MR) study assessing whether higher genetically predicted serum magnesium 
concentrations are associated with a reduced risk of intracranial aneurysm. A multivariable 
MR analysis was further performed to investigate whether any potential association may be 
mediated through effects on blood pressure.  
 
Methods 
Genetic instruments and data sources 
As instrumental variables for the primary analyses, we used single-nucleotide polymorphisms 
(SNPs) associated with serum magnesium concentrations at genome-wide significance 
(p <5×10-8) in a genome-wide association study in 23 829 individuals of European ancestry.6 
Six independent SNPs in different genetic loci and on different chromosomes were identified 
and proposed as instrumental variables for serum magnesium concentrations. In 
complementary analyses, we added two uncorrelated single-nucleotide polymorphisms in or 
near known magnesium transport genes and associated with serum magnesium 
concentrations after applying a Bonferroni-correction for the number of genetic variants 
examined in each region.6 Summary statistics data for intracranial aneurysm in individuals of 
European ancestry were obtained from a genome-wide association study of 23 cohorts 
comprising 79 429 individuals (7495 cases [69% with ruptured intracranial aneurysm, 28% 
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with unruptured intracranial aneurysm, and 3.8% with unknown rupture status] and 71 934 
controls).7 Genetic association estimates for systolic blood pressure were taken from a 
genome-wide association study of 757 601 European ancestry individuals.8  
 
Standard protocol approvals, registrations, and patient consents 
Only summary-level data were analyzed in this study, for which appropriate ethical approval 
and participant consent had previously been acquired in the original genome-wide association 
studies. The analyses were approved by the Swedish Ethical Review Authority (2019-03986). 
 
Statistical analysis 
In our main analyses, we applied the multiplicative random-effects inverse-variance weighted 
method to estimate the total association of serum magnesium concentrations with intracranial 
aneurysm.9 To assess the potential presence of directional pleiotropy, MR-Egger regression 
analysis was performed.9 Finally, to evaluate whether the results may be driven by potential 
outlier(s), we used the MR Pleiotropy RESidual Sum and Outlier method.9 T  evaluate 
whether blood pressure may mediate any association, we implemented a multivariable MR 
model with adjustment for genetically predicted systolic blood pressure. The weighted 
median method was used as a complementary method.9 We scaled all odds ratios (ORs) per 
0.1 mmol/L increase in serum magnesium concentrations, which corresponds to an 
approximate one standard deviation. Analyses were conducted using the mrrobust package10 
for Stata (StataCorp, College Station, TX) and the MendelianRandomization package11 for 
R.   
 
Data availability 
All data generated or analyzed during this study are included in Table 1. 
 





Of the six SNPs associated with serum magnesium at the genome-wide significance 
threshold, one SNP was unavailable in the intracranial aneurysm datasets and no proxy SNP 
was available at a linkage disequilibrium (LD) R2 >0.6. The other five SNPs (including one 
proxy SNP in strong LD with the original SNP) were used as instrumental variables for 
serum magnesium in the primary analyses. For the two SNPs in or near magnesium transport 
genes, we used proxy SNPs in strong or complete LD with the original SNPs (Table 1). 
Information on the SNPs used as instrumental variables and their associations with 
intracranial aneurysm is shown in Table 1. 
Genetically predicted serum magnesium concentrations were inversely associated with 
risk of intracranial aneurysm. In the analyses based on the five genome-wide significant 
SNPs, the ORs per 0.1 mmol/L increase in genetically predicted magnesium concentrations 
were 0.66 (95% CI: 0.49-0.91) for intracranial aneurysm, 0.57 (95% CI: 0.30-1.06) for 
unruptured intracranial aneurysm, and 0.67 (95% CI 0.48-0.92) for aneurysmal subarachnoid 
hemorrhage. The sensitivity analysis based on the weighted median method provided similar 
results (corresponding ORs 0.64 [95% CI: 0.45-0.91], 0.62 [95% CI: 0.32-1.20], and 0.66 
[95% CI: 0.44-0.98]). There was no evidence of directional pleiotropy (all p-values for the 
MR-Egger intercept >0.60), and no outlier was found in the MR Pleiotropy RESidual Sum 
and Outlier method. Adjustment for genetically predicted systolic blood pressure through a 
multivariable MR model attenuated the associations of genetically predicted serum 
magnesium with all three considered outcomes, consistent with a partial mediating effect 
(Figure 1). 
The complementary analyses incorporating two SNPs in or near magnesium transport 
genes yielded similar results. In these analyses based on seven SNPs, the ORs per 0.1 
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mmol/L increase in genetically predicted magnesium concentrations were 0.55 (95% CI: 
0.32-1.00) for intracranial aneurysm, 0.53 (95% CI: 0.25-1.10) for unruptured intracranial 
aneurysm, and 0.55 (95% CI: 0.32-0.97) for aneurysmal subarachnoid hemorrhage. 
 
Discussion 
This MR study provides evidence to support that higher serum magnesium concentrations 
reduces the risk of intracranial aneurysm and aneurysmal subarachnoid hemorrhage, with 
systolic blood pressure mediating part of this effect. While magnesium supplementation has 
been demonstrated to increase serum magnesium concentrations and reduce blood pressure in 
randomized clinical trials,3 to our knowledge this is the first MR study to identify a potential 
causal association between serum magnesium concentrations and risk of intracranial 
aneurysm and aneurysmal subarachnoid hemorrhage. The associations of genetically 
predicted serum magnesium with risk of intracranial aneurysm and aneurysmal subarachnoid 
hemorrhage did not fully attenuate after adjustment for genetically predicted systolic blood 
pressure, suggesting that magnesium may also affect the risk of these outcomes via other 
mechanisms. In addition to a blood pressure lowering effect, increased magnesium 
concentrations may reduce the risk of intracranial aneurysm rupture by improving endothelial 
function4, 5 and reducing oxidative stress.12  
A strength of this study is the MR design, which is less prone to confounding compared 
with conventional observational studies. Other major strengths are the relatively large 
number of cases of intracranial aneurysm and the robustness of the findings in different MR 
sensitivity analyses that are more robust to the inclusion of pleiotropic variants. Population 
stratification bias was minimized because all analyses were restricted to populations of 
European ancestry and adjustment was made for principal components for ancestry in the 
original genome-wide association studies from which summary data was used. In terms of 
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limitations, we cannot rule out that our genetic proxies for serum magnesium affect 
intracranial aneurysm risk through alternative pathways that may violate the requisite 
assumptions of MR. Another limitation is that we did not have access to appropriate data for 
a bidirectional MR analysis to investigate whether biological mechanisms predisposing to 
intracranial aneurysm influence circulating magnesium levels. Finally, the genetic variants 
used to proxy the effect of modifying serum magnesium concentration reflect small, lifelong 
effects in serum magnesium concentrations, while in contrast a clinical intervention would 
typically exert a greater change in serum magnesium concentrations later in life. Caution 
should be taken when extrapolating findings from MR to infer the effect of a clinical 
intervention, and clinical trials are warranted to guide optimal practice.  
In conclusion, this MR study provides evidence to support that higher serum magnesium 
concentrations reduce the risk of intracranial aneurysm and aneurysmal subarachnoid 
hemorrhage. These finding add to the growing body of evidence highlighting a beneficial role 
of higher magnesium for preventing cerebrovascular and cardiovascular diseases.13-15  
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Table 1. Characteristics of the single-nucleotide polymorphism used as instrumental 
variables for serum magnesium concentrations and their associations with intracranial 
aneurysm  
    
Serum magnesium 
concentrations  
IA (unruptured and 
ruptured) 
Unruptured IA Ruptured IA (aSAH) 
rsID Chr Gene EA Beta (SE)* p Beta (SE) p Beta (SE) p Beta (SE) p 
rs4072037 1 MUC1 T 0.010 (0.001) 2.01E-36 -0.038 (0.021) 0.07 -0.048 (0.039) 0.22 -0.036 (0.024) 0.14 
rs7965584† 12 ATP2B1 A 0.007 (0.001) 1.05E-16 -0.050 (0.022) 0.02 -0.098 (0.038) 0.01 -0.036 (0.027) 0.18 
rs3925584 11 DCDC5 T 0.006 (0.001) 5.20E-16 0.016 (0.022) 0.48 0.029 (0.039) 0.46 0.008 (0.026) 0.75 
rs13146355 4 SHROOM3 A 0.005 (0.001) 6.27E-13 -0.026 (0.019) 0.17 -0.010 (0.034) 0.77 -0.044 (0.023) 0.05 
rs448378 3 MDS1 A 0.004 (0.001) 1.25E-8 -0.036 (0.021) 0.09 -0.062 (0.038) 0.11 -0.024 (0.024) 0.32 
rs3740393‡ 10 CNNM2 C 0.006 (0.001) 8.58E-7 -0.174 (0.030) 1.11E-8 -0.17 (0.056) 0.002 -0.018 (0.035) 3.98E-7 
rs6746896‡ 2 CNNM4 G 0.004 (0.001) 7.01E-5 -0.004 (0.023) 0.87 0.041 (0.041) 0.32 -0.023 (0.027) 0.41 
aSAH, aneurysmal subarachnoid hemorrhage; Chr, chromosome; EA, effect allele (the allele 
that associates with higher serum magnesium concentrations); IA, intracranial aneurysm; SE, 
standard error. 
*The beta coefficients represent the increase in serum magnesium concentrations in mmol/L 
per additional effect allele.  
†The single-nucleotide polymorphism was unavailable in the intracranial aneurysm datasets 
but a proxy genetic variant (rs10858938, effect allele=G) in linkage disequilibrium (r2=0.96 
in European populations) was identified and replaced this genetic variant. 
‡Used in complementary analyses that included genetic variants in or near known 
magnesium transport genes and associated with serum magnesium after applying a 
Bonferroni-correction for the number of genetic variants assessed in each region.6 The single-
nucleotide polymorphisms described in the original study6 were unavailable in the 
intracranial aneurysm datasets, so proxy genetic variants in linkage disequilibrium (r2>0.9) 
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FIGURE TITLE  
Figure 1. Association between genetically predicted serum magnesium concentrations 
and intracranial aneurysm.  
 
FIGURE LEGEND 
Estimates are scaled per genetically predicted 0.1 mmol/L (about one standard deviation) 
increase in serum magnesium concentrations. Adjustment for genetically predicted systolic 
blood pressure was made using a multivariable Mendelian randomization model. CI, 
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